Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 12/20 | 0.67 |
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.67 |
| ▸ | CYSLTR2 | Q9NS75 | 6/20 | 0.58 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7717046 | 0.92 | CYSLTR1 (0.67) | CYSLTR1GPBAR1CYSLTR2ALOX5 | |
| SCHEMBL7455455 | 0.92 | CYSLTR1 (0.67) | CYSLTR1GPBAR1ALOX5 | |
| SCHEMBL7458688 | 0.92 | CYSLTR1 (0.67) | CYSLTR1GPBAR1ALOX5 | |
| SCHEMBL7717180 | 0.89 | CYSLTR1 (0.66) | CYSLTR1GPBAR1CYSLTR2ALOX5 | |
| SCHEMBL7009377 | 0.89 | CYSLTR1 (0.66) | CYSLTR1GPBAR1CYSLTR2ALOX5 | |
| SCHEMBL7711072 | 0.87 | GPBAR1 (0.80) | CYSLTR1GPBAR1CYSLTR2ALOX5 | |
| SCHEMBL7716691 | 0.87 | CYSLTR1 (0.88) | CYSLTR1GPBAR1CYSLTR2ALOX5 | |
| SCHEMBL10533300 | 0.86 | CYSLTR1 (0.57) | CYSLTR1GPBAR1CYSLTR2ALOX5 | |
| SCHEMBL6091338 | 0.86 | CYSLTR1 (0.61) | CYSLTR1GPBAR1CYSLTR2ALOX5 | |
| SCHEMBL7714576 | 0.86 | CYSLTR1 (0.64) | CYSLTR1GPBAR1CYSLTR2ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6376512-B1 | FOR TREATING PHYSIOLOGICAL CONDITION IN PATIENT WHEREIN SAID CONDITION IS ASSOCIATED WITH A PHYSIOLOGICALLY DETRIMENTAL LEVELS OF INSULIN, GLUCOSE, FREE FATTY ACIDS, OR TRIGLYCERIDES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-04-23 | — | — | US | disclosed |
| EP-0315399-B1 | Quinoline derivatives, their use in the treatment of hypersensitive ailments and a pharmaceutical composition containing the same | RHONE POULENC RORER INT (US) | 1996-01-10 | — | — | EP | disclosed |
| US-5059610-A | QUINOLINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF LEUKOTRIENE D4 | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1991-10-22 | — | — | US | disclosed |
| US-4920132-A | Quinoline derivatives and use thereof as antagonists of leukotriene D4 | RORER PHARMACEUTICAL CORP. (US) | 1990-04-24 | — | — | US | disclosed |